Research guide · Published July 22, 2026 · Sources checked July 22, 2026
Semaglutide vs tirzepatide vs retatrutide: a research comparison
Semaglutide, tirzepatide, and retatrutide are related acylated peptide agonists, but they are not three strengths of the same molecule. Their receptor targets, sequences, study programs, and evidence maturity differ.
Short answer
Semaglutide is primarily a GLP-1 receptor agonist, tirzepatide was designed for GIP and GLP-1 receptors, and retatrutide was designed for GIP, GLP-1, and glucagon receptors. Receptor count alone does not rank materials or make results transferable between studies.
Evidence boundary: This page compares published molecular and study designs. It does not provide dosing, administration, purchasing, or human-use guidance. Catalog materials are supplied only for qualified in vitro laboratory research and are not for human or animal use.
Comparison at a glance
| Research dimension | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Receptors studied | GLP-1R | GIPR and GLP-1R | GIPR, GLP-1R, and GCGR |
| Common literature name | Semaglutide | LY3298176 | LY3437943 |
| Design description | Acylated GLP-1 analogue | Unimolecular dual agonist | Unimolecular triple agonist |
| Comparison limit | Different doses and trials cannot be normalized by name alone | Dual activity is assay- and species-dependent | Triple activity does not establish superiority in every model |
How to interpret the comparison
The three molecules must be compared at the level of sequence, modification, receptor assay, species, and protocol. A clinical outcome from one controlled investigational product does not validate a separately sourced research material.
Direct head-to-head evidence is more informative than comparing percentages across unrelated studies. Even then, the tested formulations, populations, endpoints, and oversight remain part of the result.
Primary sources
- Lau et al., Journal of Medicinal Chemistry (2015) — Semaglutide molecular design, receptor activity, albumin affinity, and experimental pharmacokinetics. DOI: 10.1021/acs.jmedchem.5b00726
- Coskun et al., Molecular Metabolism (2018) — Discovery and translational studies of the dual GIP/GLP-1 receptor agonist LY3298176. DOI: 10.1016/j.molmet.2018.09.009
- Coskun et al., Cell Metabolism (2022) — Receptor assays and translational studies of the triple agonist LY3437943. DOI: 10.1016/j.cmet.2022.07.013
Continue in the research library
Prepared by The Pep Labs Research Editorial Team. This evidence summary is not medical advice and contains no dosing or administration guidance.